Understanding the Future of Medicine and What it Means for Your Company

Crosstree’s advisors have end-to-end experience in the pharma services, research, and development space, and has worked with companies positioned from discovery and preclinical, to clinical development and lab services, to supply and commercialization.

As pharmaceutical companies shift toward combination product development programs and more complex test-and-treat therapies, patient-centricity has become a focal point. Crosstree understands how each company supports the patient’s journey — either directly or secondarily by facilitating better research and development — and can identify the most viable buyers based on current and emerging needs.

Crosstree has provided buy- and sell-side financial guidance through the rise of targeted medicine. Today, Crosstree is spearheading transactions for innovative growth companies and established market leaders shifting toward precision and specialty medicine strategies.

For monthly coverage of M&A, recapitalization, and growth financing transactions and to stay apprised of valuations and trends, subscribe to Crosstree’s monthly BlueBooks.

SUBSCRIBE NOW

Click image to view larger

Recent Deals

ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally
anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally
OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials
Clairvest Acquires Boca Biolistics to Accelerate Growth of Infectious Disease and Oncological Biobanking Capabilities